Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Kriya Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to advance Kriya’s portfolio of gene therapies designed to block complement C3 and C5 for retinal diseases using Everads' suprachoroidal delivery device.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 27, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Kriya Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the deal in which the gene therapy company was given a right to negotiate a worldwide license related to specific retinal targets, the companies will explore the feasibility of using Everads' technology to deliver proprietary viral vectors to the c...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 30, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Collaboration